Table 2.
Effect of chronic elafibranor (elaf) treatment on the inflammatory profiles of HFD mice with steatohepatitis and CKD.
| NC-24w | HFD-24w | HFD-elaf | |
|---|---|---|---|
| Kidney weight (mg) | 356 ± 10 | 423 ± 9∗ | 318 ± 34 |
| [triglyceride, TG, mg/dL] | 57 ± 3.9 | 299 ± 28∗ | 211 ± 14# |
| Hepatic TG levels (mg/g) | 98 ± 7 | 240 ± 18∗ | 200 ± 10# |
| [fasting glucose] (mg/dL) | 116 ± 13 | 243 ± 28∗ | 203 ± 9# |
| [fasting Insulin] (ng/mL) | 1.9 ± 0.2 | 6.9 ± 0.85∗ | 5.2 ± 0.8 |
| Homeostasis model assessment-insulin-resistance (HOMA-IR) index | 3.8 ± 0.4 | 28.8 ± 6.4∗ | 18.1 ± 1.1# |
| [Aspartate aminotransferase] (AST, U/L) | 40.9 ± 1.6 | 117.3 ± 20.1∗ | 79.5 ± 4.3# |
| [Alanine aminotransferase] (ALT, U/L) | 46.8 ± 10.3 | 183.2 ± 6.8∗ | 104.2 ± 13.7# |
| [IL-6, pg/mL] | 144 ± 18 | 223 ± 35∗ | 168 ± 9# |
| Kidney IL-6 (pg/mg protein) | 1.8 ± 0.4 | 7 ± 0.8∗ | 6.2 ± 1.9 |
| [TNFα, pg/mL] | 12 ± 5 | 40 ± 11∗ | 29 ± 8## |
| Renal TNFα (pg/mg protein) | 4 ± 0.8 | 16 ± 2.3∗ | 9 ± 1.1# |
| Renal MPO activity (U/g) | 8.6 ± 1.5 | 51 ± 20∗ | 31 ± 4# |
| Renal caspase-3 activity (pmol/µg protein) | 35 ± 1 | 90 ± 5∗ | 72 ± 3# |
NC-24w/HFD-24w: mice receiving 24-week high-fat diet (HFD) or normal chow (NC) feeding and vehicle treatment; NC-elaf/HFD-elaf: HFD- or NC-fed mice receiving 12-week elafibranor treatment from 13th to 24th week of either HFD or NC feeding; HOMA-IR: calculated as ([fasting glucose]×[fasting insulin])/58.32. ∗, ∗∗p<0.05,0.01 vs. NC-group; #,##p<0.05, 0.01 vs. HFD-group.